538 related articles for article (PubMed ID: 36171633)
21. E3 Ubiquitin Ligase RNF125 Suppresses Immune Escape in Head and Neck Squamous Cell Carcinoma by Regulating PD-L1 Expression.
Jiang C; He L; Xiao S; Wu W; Zhao Q; Liu F
Mol Biotechnol; 2023 Jun; 65(6):891-903. PubMed ID: 36344734
[TBL] [Abstract][Full Text] [Related]
22. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
24. HNRNPC Regulates GLUT1/LDHA Pathway by Stabilizing FOXM1 mRNA to Promote the Progression and Aerobic Glycolysis of Multiple Myeloma.
Wu N; Zhu Y
Ann Clin Lab Sci; 2024 Jan; 54(1):56-65. PubMed ID: 38514068
[TBL] [Abstract][Full Text] [Related]
25. Propofol disrupts cell carcinogenesis and aerobic glycolysis by regulating circTADA2A/miR-455-3p/FOXM1 axis in lung cancer.
Zhao H; Wei H; He J; Wang D; Li W; Wang Y; Ai Y; Yang J
Cell Cycle; 2020 Oct; 19(19):2538-2552. PubMed ID: 32857667
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC).
Wang Y; Zhou Y; Cao S; Sun Y; Dong Z; Li C; Wang H; Yao Y; Yu H; Song X; Li M; Wang J; Wei M; Yang G; Yang C
Bioorg Chem; 2021 Jun; 111():104833. PubMed ID: 33839580
[TBL] [Abstract][Full Text] [Related]
27. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1.
Cotton AD; Nguyen DP; Gramespacher JA; Seiple IB; Wells JA
J Am Chem Soc; 2021 Jan; 143(2):593-598. PubMed ID: 33395526
[TBL] [Abstract][Full Text] [Related]
28. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
29. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
30. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
31. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
Koh YW; Lee SJ; Han JH; Haam S; Jung J; Lee HW
Lung Cancer; 2019 Mar; 129():41-47. PubMed ID: 30797490
[TBL] [Abstract][Full Text] [Related]
33. Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.
Shang R; Wang M; Dai B; Du J; Wang J; Liu Z; Qu S; Yang X; Liu J; Xia C; Wang L; Wang D; Li Y
Mol Oncol; 2020 Jun; 14(6):1381-1396. PubMed ID: 32174012
[TBL] [Abstract][Full Text] [Related]
34. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques.
Chen S; Cui J; Chen H; Yu B; Long S
Eur J Med Chem; 2023 Dec; 262():115911. PubMed ID: 37924709
[TBL] [Abstract][Full Text] [Related]
35. PROTACs: A novel strategy for cancer drug discovery and development.
Han X; Sun Y
MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
[TBL] [Abstract][Full Text] [Related]
36. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
[TBL] [Abstract][Full Text] [Related]
37. Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.
Lin Z; Garcia BA; Lv D
Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202316581. PubMed ID: 38059785
[TBL] [Abstract][Full Text] [Related]
38. Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization.
Schwalm MP; Krämer A; Dölle A; Weckesser J; Yu X; Jin J; Saxena K; Knapp S
Cell Chem Biol; 2023 Jul; 30(7):753-765.e8. PubMed ID: 37354907
[TBL] [Abstract][Full Text] [Related]
39. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
40. An In Vitro Pull-down Assay of the E3 Ligase:PROTAC:Substrate Ternary Complex to Identify Effective PROTACs.
Bondeson DP; Smith BE; Buhimschi AD
Methods Mol Biol; 2021; 2365():135-150. PubMed ID: 34432242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
